A new hope for early gonarthrosis treatment using a biotechnological therapeutic drug to regenerate cartilage by intra-articular knee injection

Projektinformationen

RHYP

ID Finanzhilfevereinbarung: 766606

DOI 10.3030/766606

Projekt abgeschlossen

EK-Unterschriftsdatum 31 Mai 2017

Startdatum 1 Juni 2017

Enddatum 30 November 2020

Finanziert unter

• INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology

Gesamtkosten € 3 008 500,00

EU-Beitrag € 2 105 950,00

Koordiniert durch

REGULAXIS
France

Leistungen

Documents, reports (4)

Report on volunteers recruitment and clinical trial launch
Copy of CTA folder
Ethical protocols reports and authorization approval copies
Report to present RHYP corporate identity and first leaflet and promotion material models

Veröffentlichungen

Peer reviewed articles (1)

REG-O3 chimeric peptide combining growth hormone and somatostatin sequences improves joint function and prevents cartilage degradation in rat model of traumatic knee osteoarthritis

Autoren: Rodrick Montjean, Sonia Escaich, Raffaello Paolini, Claude Carelli, Sébastien Pirson, Thibaut Neutelings, Yves Henrotin, Christelle Vêtu
Veröffentlicht in: PLOS ONE, Ausgabe 15/4, 2020, Seite(n) e0231240, ISSN 1932-6203
Herausgeber: Public Library of Science
DOI: 10.1371/journal.pone.0231240